WCN26-5384 Managing Fulminant Liver Failure from Anti-Tuberculosis Drug-Induced Hepatotoxicity Using DPMAS: A Case Report

Read full text Summarise with VIRAT
Authors: ROLAND DELA CRUZ, Czarina Jean De Jesus
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Drug-induced liver injury (DILI) remains one of the most challenging complications in clinical medicine, particularly in regions with high infectious disease burdens where multidrug regimens are often indispensable. Among the most common agents responsible are the first-line anti-tuberculosis (anti-TB) drugs—isoniazid, rifampicin, and pyrazinamide—which are widely used as part of standard treatment protocols for tuberculosis. In the Philippines, where TB remains a major public health concern, DILI poses a substantial clinical problem, contributing to cases of acute liver failure (ALF) that carry high morbidity and mortality (Andrade, 2019).

Fields of Study & Subjects

Drug-Induced Hepatotoxicity and Protection Liver Disease and Transplantation Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105267–105267
Publication date
25 March 2026
Language
EN